SpringWorks Therapeutics, Inc. (SWTX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Stamford, CT, アメリカ. 現CEOは Saqib Islam.
SWTX を有する IPO日 2019-09-13, 368 名の正社員, に上場 NASDAQ Global Select, 時価総額 $3.54B.
SpringWorks Therapeutics, Inc. is a biopharmaceutical company founded in 2017 that acquires, develops, and commercializes medicines targeting underserved patient populations with rare diseases and cancer. The company's lead product candidate, nirogacestat, is an oral gamma secretase inhibitor currently in Phase III clinical trials for desmoid tumors, while its clinical pipeline includes mirdametinib, a MEK inhibitor being evaluated for neurofibromatosis type 1-associated plexiform neurofibromas and solid tumors, as well as BGB-3245 for BRAF-mutant cancers. SpringWorks has established strategic collaborations and licensing agreements with major pharmaceutical companies including BeiGene, GlaxoSmithKline, Pfizer, and others to advance combination therapies and expand its therapeutic capabilities. Headquartered in Stamford, Connecticut, the company focuses on developing innovative small molecule inhibitors across multiple oncology and rare disease indications.
